Skip to Content


In the US, Cabazitaxel (cabazitaxel systemic) is a member of the drug class mitotic inhibitors and is used to treat Prostate Cancer.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Cytostatic agent

Microtubule inhibitor


Chemical Names

(2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimetoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate-propan-2-one (1:1)

1-hydroxy-7β,10β-dimetyoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate] (WHO)

Foreign Names

  • Cabazitaxelum (Latin)
  • Cabazitaxel (German)
  • Cabazitaxel (French)
  • Cabazitaxel (Spanish)

Generic Names

  • Cabazitaxel (OS: USAN, BAN)
  • RPR 116258A (IS)
  • Taxoid XRP6258 (IS)
  • TXD 258 (IS)
  • XRP 6258 (IS)

Brand Names

  • Cabazil
    Varifarma, Argentina
  • Cecalter
    Tuteur, Argentina
  • Jevtana
    Aventis, Serbia; Orifarm, Norway; Sanofi, Denmark; Sanofi, Dominican Republic; Sanofi, United Kingdom; Sanofi, Guatemala; Sanofi, Ireland; Sanofi, Japan; Sanofi, Panama; Sanofi, Sweden; Sanofi Aventis, Chile; Sanofi Belgium, Belgium; Sanofi Clir SNC, Greece; Sanofi Franta, Romania; Sanofi Israel, Israel; Sanofi Oy, Finland; Sanofi Sağlik, Turkey; Sanofi-Aventis, Argentina; Sanofi-Aventis, Australia; Sanofi-Aventis, Bosnia & Herzegowina; Sanofi-Aventis, Canada; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Cyprus; Sanofi-Aventis, Czech Republic; Sanofi-Aventis, Estonia; Sanofi-Aventis, Spain; Sanofi-Aventis, France; Sanofi-Aventis, Hong Kong; Sanofi-Aventis, Honduras; Sanofi-Aventis, Croatia (Hrvatska); Sanofi-Aventis, Indonesia; Sanofi-Aventis, Iceland; Sanofi-Aventis, Lithuania; Sanofi-Aventis, Malaysia; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Norway; Sanofi-Aventis, Philippines; Sanofi-Aventis, Poland; Sanofi-Aventis, Singapore; Sanofi-Aventis, Slovakia; Sanofi-Aventis, El Salvador; Sanofi-Aventis, Thailand; Sanofi-Aventis, United States; Sanofi-Aventis Deutschland, Germany; Sanofi-Aventis Farmaceutica, Brazil; Sanofi-Aventis Groupe, Slovenia
  • Jevtana 60mg
    Haemato Pharm, Austria; Orifarm, Austria; Sanofi Belgium, Luxembourg; Sanofi-Aventis, Austria; Sanofi-Aventis, Switzerland; Sanofi-Aventis, Hungary; Sanofi-Aventis, Oman
  • Proazitax
    Eurofarma, Brazil
  • Zitat
    LKM, Argentina


BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.